• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Bruker Acquires Prolab Instruments to Augment Multiomics Solutions

Share:

January 22, 2022

Highlights on this story:
  • Unique Zirconium™ nano-LC to cap-LC pump technology for 4 nL/min to 10 μL/min flow rates with split-less UHPLC operation for optimized proteomics results
  • Innovative, proprietary Zirconium Cube™ autosampler with mobile injection unit technology for precise, ultra-low volume injections in high sensitivity single-cell proteomics and immunopeptidomics
  • ZircoFIT™ UHPLC fittings for robust, easy-to-use nano- to cap-LC fused silica connections to enhance chromatographic peak shapes
  • New Zirconium™ Ultra UHPLC System for cap-LC high-throughput proteomics and metabolomics

Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Prolab Instruments GmbH, a Swiss technology company specialized in low-flow, high precision liquid chromatography technology, and systems. The financial terms of the transaction were not disclosed.

Established in 1988, ProLab’s innovations center around micro and nano-UHPLC pump technology, resulting in the development of the unique Zirconium™ split-less pump technology for flow rates from nano-flow (4-800 nL/min) to cap-flow (1-10 µL/min) regimes. The Zirconium™ Ultra nano- and cap-UHPLC system supports a broad range of flow rates from 4 nL/min to 10 µL/min at 1000 bar (15,000 psi), and is suitable for cap-LC in high-throughput proteomics and metabolomics.

Recently, Prolab launched the innovative Zirconium Qube autosampler with the proprietary mobile injection unit technology that integrates the injector valve and loop and moves to each sample vial to minimize carry-over, thereby enabling ultra-low volume injections with high precision. This unique high-precision injection capability has the potential to further enhance single-cell proteomics.

Leveraging nearly 30 years of experience with low flow rates and minimized dead volumes, Prolab also offers unique Zircofit™ fused silica connectors known for flexibility, robustness, and ease of use.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Mr. Werner Doebelin, the Founder and CEO of Prolab, said: “We are pleased to become part of Bruker and augment the proteomics and metabolomics workflows of high-performance mass spectrometry systems like the timsTOF or scimaX® MRMS platforms. Our Zirconium pump is already part of the Bruker high-performance nanoElute system. Being part of Bruker allows us to increase the pace of product innovation, and we are looking forward to bringing our Mobile Injection Unit Technology to market to further improve performance and robustness in key applications, like single-cell proteomics and lipidomics.”

Mr. Juergen Srega, the President of the Bruker CALID Group, explained: “Given the enormous sensitivity improvements of our timsTOF Pro 2 and timsTOF SCP mass spectrometers, our customers are working with lower and lower sample amounts. Prolab’s innovative mobile injector technology on the Zirconium Qube autosampler provides high-precision, low volume injections with minimal sample loss and carryover, as well as faster cycle times. Zirconium perfectly complements our ultra-high sensitivity unbiased, deep 4D proteomics, immunopeptidomics, and single-cell proteomics solutions.”

Source: Biospace

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Neurophet gears for 2024 IPO after $15M Series C raise and more digital health fundingsNeurophet gears for 2024 IPO after $15M Series C raise and more digital health fundings
  • Innovaccer, Roche Partner to Develop Clinical Decision Support SolutionsInnovaccer, Roche Partner to Develop Clinical Decision Support Solutions
  • The American Board of Telehealth Offers New Certificate Focused on Virtual Mental HealthThe American Board of Telehealth Offers New Certificate Focused on Virtual Mental Health
  • Omega 3 Products Market 2019 Global Industry Growth, Size, Demand, Trends, Insights and Forecast 2025Omega 3 Products Market 2019 Global Industry Growth, Size, Demand, Trends, Insights and Forecast 2025
  • Real-World Study Uses AI to Identify Undiagnosed Dementia in Primary CareReal-World Study Uses AI to Identify Undiagnosed Dementia in Primary Care
  • Thermo Fisher Scientific Completes Acquisition of CorEvitasThermo Fisher Scientific Completes Acquisition of CorEvitas
  • Colorado Health Plan Deploys Texting for COVID-19 Medicaid Outreach for Its MembersColorado Health Plan Deploys Texting for COVID-19 Medicaid Outreach for Its Members
  • Cell Biotech Acquire a European Patent for Anticancer Protein P8 Originated from Lactobacillus RhamnosusCell Biotech Acquire a European Patent for Anticancer Protein P8 Originated from Lactobacillus Rhamnosus

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications